A team at the Cell Therapy Research Institute led by Christine Podrini (2023) report that Acne is a common inflammatory skin condition, and the Lactiplantibacillus plantarum serum has shown enhanced viability of L. plantarum bacteria, potentially offering a new approach to acne management. The serum did not exhibit toxic responses on the skin and resulted in improved viability in subjects. Acne is a complex disease that can impact quality of life and lead to scarring. Lactiplantibacillus plantarum aims to prevent the production of inflammatory mediators and inhibit acne-causing bacteria, offering a potential solution for acne management.
SUMMARY
- Acne remains the most common inflammatory dermatosis treated worldwide
- The impact of the combined components found in the SkinDuoTM serum that included mannitol, hyaluronic acid and vitamin B1 on L. plantarum viability was assessed by comparing it to the viability of the L. plantarum solemnly
- The proportion of alive bacteria was overall stable over time, an increased number of L. plantarum was observed after 7 days and 4 weeks for the SkinDuoTM dry formulation when compared to L. plantarum only (Figure S1), suggesting an enhanced viability
- The results of this study have demonstrated the potential of SkinDuoTM as a new approach to acne management
- The generation of an inflammatory process plays a key role in the pathophysiology of acne, and SkinDuoTM is designed to prevent the production of inflammatory mediators
- Resulting 9/10 subjects that applied the serum SkinDuoTM resulted in more than 50% mean viability when compared to initial time 0
- Serum did not exhibit toxic responses on the skin, and the topical formulation is suitable for the application of live bacteria in a sufficient dose on the skin that is delivered in a viable state
ABSTRACT
The tailoring of the skin microbiome is challenging and is a research hotspot in the pathogenesis of immune-mediated inflammatory skin diseases such as acne. Commonly encountered preservatives used as functional ingredients have an impact on the skin microbiota and are known to inhibit the survival of skin commensal bacteria. The selected species is Lactiplantibacillus plantarum. Ex vivo human skin models were used as a test system to assess the strain viability which was then validated on healthy volunteers. Lactiplantibacillus plantarum showed increased viability over time for in vitro skin models and a stable viability of over 50% on healthy skin. The strain was tested on human primary sebocytes obtained from sebaceous gland rich areas of facial skin and inoculated with the most abundant bacteria from the skin microbiota. Results on human ex vivo sebaceous gland models with the virulent phylotype of Cutibacterium acnes and Staphylococcus epidermidis present a significant reduction in viability, lipid production, and anti-inflammatory markers. We have developed an innovative anti-acne serum with L. plantarum that mimics the over-production of lipids, anti-inflammatory properties, and improves acne-disease skin models. Based on these results, we suggest that Lactiplantibacillus plantarum may be introduced as an acne-mitigating agent.
RESULTS AND CONCLUSION
Acne is a skin disease with an inflammatory background. Topical antibiotics represent the most common first-line therapy for acne even though prolonged treatment may not result in an effective cure. However, topical antibiotic agents are most frequently used for mild inflammatory disease, including papulopustular acne. For patients with more severe extensive acne skin disease, oral antibiotics are used together with topical retinoids.
REFERENCE
Leave A Comment